FDA Approved: GILOTRIF — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Gilotrif (afatinib) submitted by Boehringer Ingelheim, updating labeling for the drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gilotrif (Afatinib)

Snippet

SUPPL AP for GILOTRIF (AFATINIB)